Answers are grounded in this paper and cite their sources.
These results show that a CGP assay targeting ~1.1 Mb of coding genome can accurately assess TMB compared with sequencing the whole exome. Using this method, we find that many disease types have a substantial portion of patients with high TMB who might benefit from immunotherapy. Finally, we identify novel, recurrent promoter mutations in PMS2, which may be another example of regulatory mutations contributing to tumorigenesis.
No takes yet. Share an insight, caveat, or question.
Chalmers et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: